Literature DB >> 18399781

Clinical investigation of hospitalized human cases of West Nile virus infection in Houston, Texas, 2002-2004.

Kristy O Murray1, S Baraniuk, M Resnick, R Arafat, C Kilborn, R Shallenberger, T L York, D Martinez, M Malkoff, N Elgawley, W McNeely, S A Khuwaja.   

Abstract

The objective of this study was to describe the clinical features of cases hospitalized with West Nile virus (WNV) infections and identify clinical parameters that could potentially predict poor outcome (death). Retrospective medical chart reviews were completed for 172 confirmed cases of WNV infection hospitalized in the Houston, Texas, metropolitan area between 2002 and 2004. Of the 172 patients, 113 had encephalitis which resulted in 17 deaths, 47 had meningitis, and 12 had uncomplicated fever. Risk factors associated with progression from encephalitis to death were absence of pleocytosis in the cerebrospinal fluid, renal insufficiency, requiring intubation and mechanical ventilation, presence of myoclonus or tremors, and loss of consciousness. These findings can aid physicians in evaluating their patients suspected of WNV infection and determining outcomes in their patients with confirmed WNV neuroinvasive disease.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18399781     DOI: 10.1089/vbz.2007.0109

Source DB:  PubMed          Journal:  Vector Borne Zoonotic Dis        ISSN: 1530-3667            Impact factor:   2.133


  17 in total

1.  Clinical and radiological predictors of outcome for Murray Valley encephalitis.

Authors:  David J Speers; James Flexman; Christopher C Blyth; Nirooshan Rooban; Edward Raby; Ganesh Ramaseshan; Susan Benson; David W Smith
Journal:  Am J Trop Med Hyg       Date:  2013-01-07       Impact factor: 2.345

2.  Immune markers associated with host susceptibility to infection with West Nile virus.

Authors:  Feng Qian; Juilee Thakar; Xiaoling Yuan; Melissa Nolan; Kristy O Murray; William T Lee; Susan J Wong; Hailong Meng; Erol Fikrig; Steven H Kleinstein; Ruth R Montgomery
Journal:  Viral Immunol       Date:  2014-03       Impact factor: 2.257

3.  West nile virus neuroinvasive disease.

Authors:  Roberta L Debiasi
Journal:  Curr Infect Dis Rep       Date:  2011-08       Impact factor: 3.725

4.  A Preliminary Study of Proinflammatory Cytokines and Depression Following West Nile Virus Infection.

Authors:  Allison Lino; Timothy A Erickson; Melissa S Nolan; Kristy O Murray; Shannon E Ronca
Journal:  Pathogens       Date:  2022-06-04

Review 5.  West Nile virus and its emergence in the United States of America.

Authors:  Kristy O Murray; Eva Mertens; Philippe Despres
Journal:  Vet Res       Date:  2010 Nov-Dec       Impact factor: 3.683

6.  Immune response to the West Nile virus in aged non-human primates.

Authors:  Anne M Wertheimer; Jennifer L Uhrlaub; Alec Hirsch; Guruprasad Medigeshi; Jerald Sprague; Alfred Legasse; Jennifer Wilk; Clayton A Wiley; Peter Didier; Robert B Tesh; Kristy O Murray; Michael K Axthelm; Scott W Wong; Janko Nikolich-Žugich
Journal:  PLoS One       Date:  2010-12-02       Impact factor: 3.240

7.  Persistence of detectable immunoglobulin M antibodies up to 8 years after infection with West Nile virus.

Authors:  Kristy O Murray; Melissa N Garcia; Chris Yan; Rodion Gorchakov
Journal:  Am J Trop Med Hyg       Date:  2013-09-23       Impact factor: 2.345

8.  Measuring the burden of arboviral diseases: the spectrum of morbidity and mortality from four prevalent infections.

Authors:  A Desirée Labeaud; Fatima Bashir; Charles H King
Journal:  Popul Health Metr       Date:  2011-01-10

9.  Prevalence of chronic kidney disease and progression of disease over time among patients enrolled in the Houston West Nile virus cohort.

Authors:  Melissa S Nolan; Amber S Podoll; Anne M Hause; Katherine M Akers; Kevin W Finkel; Kristy O Murray
Journal:  PLoS One       Date:  2012-07-06       Impact factor: 3.240

10.  Morbidity, mortality and long-term sequelae of West Nile virus disease in Québec.

Authors:  N Ouhoumanne; A-M Lowe; A Fortin; D Kairy; A Vibien; J K-Lensch; T-N Tannenbaum; F Milord
Journal:  Epidemiol Infect       Date:  2018-03-28       Impact factor: 4.434

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.